Article
The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation.
Thrombosis and haemostasis - 1 May 1999
Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H
Abstract excerpt
The results concerning the risk of recurrent venous thromboembolism (VTE) in carriers of the G1691A mutation in the coagulation factor V gene are not consistent and this risk in carriers of the G20210A polymorphism in the prothrombin gene has hitherto not been reported. We followed 534 patients for 48 months after their first episode of objectively documented VTE. The prevalence of the G1691A allele in 467...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.